Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
In Vogt-Koyanagi-Harada disease, patients with high IL-17 production from concanavalin A stimulated PBMC were older, took longer time to improve visual acuity, and needed greater amount of corticosteroid than patients with low IL-17.Prognosis of the patients with high IL-17 production with PBMC was suggested to be worse than the patients with low IL-17.IL-17 production from PBMC can be a disease activity marker in Vogt-Koyanagi-Harada disease.
|